Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …

Background The optimal perioperative chemotherapeutic regimen for locally advanced
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …

The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric
adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant …

The current tumour-node-metastasis (TNM) staging system alone cannot provide adequate
information for prognosis and adjuvant chemotherapy benefits in patients with gastric cancer …

Abstract Aims Long non-coding RNAs (lncRNAs), as one of the components of exosomes
derived from cancer-associated fibroblasts (CAFs), exhibit a crucial role in the pathogenesis …

The rising cancer incidence rate in China poses a substantial public health concern,
although there have been remarkable improvements in the country's cancer mortality and …

In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …